Hochschulschrift
Role of prostanoid receptor EP1 in the progression of non-small cell lung cancer (NSCLC)
- Alternative title
-
Die Rolle des Prostanoid-Rezeptors EP1 bei der Progression des nicht-kleinzelligen Lungenkarzinoms (NSCLC)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Gießen, Justus-Liebig-Universität, Diss., 2013
- Keyword
-
Krebs
Onkologie
- Event
-
Veröffentlichung
- (where)
-
Gießen
- (who)
-
Universitätsbibliothek
- (when)
-
2013
- Creator
- URN
-
urn:nbn:de:hebis:26-opus-94987
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
12.04.2032, 12:11 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
- Pamarthi, Pavan Kumar
- Universitätsbibliothek
Time of origin
- 2013
Other Objects (12)
Role of prostanoid receptor EP1 in the progression of non-small cell lung cancer (NSCLC)
ASCO 2020 non-small lung cancer (NSCLC) personal highlights
Chronic stress promotes non-small cell lung cancer (NSCLC) progression through circMBOAT2 upregulation mediated by CTCF
Fibroblast growth factor 11 (FGF11) promotes non-small cell lung cancer (NSCLC) progression by regulating hypoxia signaling pathway
Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC)
MicroRNA genetic signature in non-small cell lung cancer (NSCLC) Egyptian patients
TFAP2A drives non-small cell lung cancer (NSCLC) progression and resistance to targeted therapy by facilitating the ESR2-mediated MAPK pathway
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
Patients’ confidence in treatment decisions for early stage non-small cell lung cancer (NSCLC)
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC)
Role of prostanoid receptor EP1 in the progression of non-small cell lung cancer (NSCLC)
ASCO 2020 non-small lung cancer (NSCLC) personal highlights
Chronic stress promotes non-small cell lung cancer (NSCLC) progression through circMBOAT2 upregulation mediated by CTCF
Fibroblast growth factor 11 (FGF11) promotes non-small cell lung cancer (NSCLC) progression by regulating hypoxia signaling pathway
Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC)
MicroRNA genetic signature in non-small cell lung cancer (NSCLC) Egyptian patients
TFAP2A drives non-small cell lung cancer (NSCLC) progression and resistance to targeted therapy by facilitating the ESR2-mediated MAPK pathway
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
Patients’ confidence in treatment decisions for early stage non-small cell lung cancer (NSCLC)
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC)
Role of prostanoid receptor EP1 in the progression of non-small cell lung cancer (NSCLC)
ASCO 2020 non-small lung cancer (NSCLC) personal highlights
Chronic stress promotes non-small cell lung cancer (NSCLC) progression through circMBOAT2 upregulation mediated by CTCF
Fibroblast growth factor 11 (FGF11) promotes non-small cell lung cancer (NSCLC) progression by regulating hypoxia signaling pathway
Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC)
MicroRNA genetic signature in non-small cell lung cancer (NSCLC) Egyptian patients
TFAP2A drives non-small cell lung cancer (NSCLC) progression and resistance to targeted therapy by facilitating the ESR2-mediated MAPK pathway
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
Patients’ confidence in treatment decisions for early stage non-small cell lung cancer (NSCLC)
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment